160 related articles for article (PubMed ID: 18506140)
1. Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients.
Ferrandina G; Petrillo M; Carbone A; Zannoni G; Martinelli E; Prisco M; Pignata S; Breda E; Savarese A; Scambia G
Br J Cancer; 2008 Jun; 98(12):1910-5. PubMed ID: 18506140
[TBL] [Abstract][Full Text] [Related]
2. Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma.
Kucukgoz Gulec U; Gumurdulu D; Guzel AB; Paydas S; Seydaoglu G; Acikalin A; Khatib G; Zeren H; Vardar MA; Altintas A
Arch Gynecol Obstet; 2014 Feb; 289(2):393-8. PubMed ID: 23974278
[TBL] [Abstract][Full Text] [Related]
3. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M
Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297
[TBL] [Abstract][Full Text] [Related]
4. [The expression of MRP, GST-pi, Topo IIalpha and COX-2 in epithelial ovarian cancer and its relationship to drug resistance and prognosis].
Cao DY; Shen K; Yang JX; Guan J
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(25):1738-41. PubMed ID: 17919376
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
[TBL] [Abstract][Full Text] [Related]
6. DNA topoisomerase II alpha: a favorable prognostic factor in colorectal caner.
Gao XH; Yu ZQ; Zhang C; Bai CG; Zheng JM; Fu CG
Int J Colorectal Dis; 2012 Apr; 27(4):429-35. PubMed ID: 22076611
[TBL] [Abstract][Full Text] [Related]
7. DNA topoisomerase IIalpha and -beta expression in human ovarian cancer.
Withoff S; van der Zee AG; de Jong S; Hollema H; Smit EF; Mulder NH; de Vries EG
Br J Cancer; 1999 Feb; 79(5-6):748-53. PubMed ID: 10070864
[TBL] [Abstract][Full Text] [Related]
8. DNA topoisomerase IIalpha in multiple myeloma: a marker of cell proliferation and not drug resistance.
Wilson CS; Medeiros LJ; Lai R; Butch AW; McCourty A; Kelly K; Brynes RK
Mod Pathol; 2001 Sep; 14(9):886-91. PubMed ID: 11557785
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.
Kreisholt J; Sorensen M; Jensen PB; Nielsen BS; Andersen CB; Sehested M
Br J Cancer; 1998 May; 77(9):1469-73. PubMed ID: 9652763
[TBL] [Abstract][Full Text] [Related]
10. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM
Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851
[TBL] [Abstract][Full Text] [Related]
11. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
Du Y; Zhou Q; Yin W; Zhou L; Di G; Shen Z; Shao Z; Lu J
Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase IIalpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis.
Faggad A; Darb-Esfahani S; Wirtz R; Sinn B; Sehouli J; Könsgen D; Lage H; Weichert W; Noske A; Budczies J; Müller BM; Buckendahl AC; Röske A; Eldin Elwali N; Dietel M; Denkert C
Mod Pathol; 2009 Apr; 22(4):579-88. PubMed ID: 19270648
[TBL] [Abstract][Full Text] [Related]
13. Tissue microarray analysis of topoisomerase IIalpha protein in gastric adenocarcinomas: histogenetic and prognostic implications.
Wang G; Huang H; Gao J; Chen P; You W; Wu B; Wang M
Cancer Genomics Proteomics; 2011; 8(3):127-33. PubMed ID: 21518818
[TBL] [Abstract][Full Text] [Related]
14. Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer.
Naniwa J; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Shimogai R; Kawaguchi W; Sato S; Terakawa N
Int J Gynecol Cancer; 2007; 17(1):76-82. PubMed ID: 17291235
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical study on topoisomerase IIalpha, Ki-67 and cytokeratin-19 in oral lichen planus lesions.
Mattila R; Alanen K; Syrjänen S
Arch Dermatol Res; 2007 Jan; 298(8):381-8. PubMed ID: 17072627
[TBL] [Abstract][Full Text] [Related]
16. DNA topoisomerase IIalpha expression in optic pathway gliomas of childhood.
Bredel M; Slavc I; Birner P; Czech T; Haberler C; Ströbel T; Wolfsberger S; Budka H; Hainfellner JA
Eur J Cancer; 2002 Feb; 38(3):393-400. PubMed ID: 11818205
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase IIα as a prognostic factor in pituitary tumors.
Trofimiuk-Müldner M; Bałdys-Waligórska A; Sokołowski G; Adamek D; Hubalewska-Dydejczyk A; Gołkowski F
Pol Arch Med Wewn; 2014; 124(10):500-8. PubMed ID: 25692206
[TBL] [Abstract][Full Text] [Related]
18. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer.
Nakopoulou L; Lazaris AC; Kavantzas N; Alexandrou P; Athanassiadou P; Keramopoulos A; Davaris P
Pathobiology; 2000; 68(3):137-43. PubMed ID: 11174071
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome.
Schrader C; Meusers P; Brittinger G; Teymoortash A; Siebmann JU; Janssen D; Parwaresch R; Tiemann M
Leukemia; 2004 Jul; 18(7):1200-6. PubMed ID: 15116121
[TBL] [Abstract][Full Text] [Related]
20. Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells.
Wray J; Williamson EA; Royce M; Shaheen M; Beck BD; Lee SH; Nickoloff JA; Hromas R
PLoS One; 2009; 4(4):e5323. PubMed ID: 19390626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
